Barbero M, Burgos S, Roca I, Navarro L, Cairo F
Medicine (Baltimore). 2025; 104(6):e41378.
PMID: 39928808
PMC: 11813046.
DOI: 10.1097/MD.0000000000041378.
Mucenic M
World J Hepatol. 2024; 16(2):135-139.
PMID: 38495280
PMC: 10941753.
DOI: 10.4254/wjh.v16.i2.135.
Taubert R, Engel B
Inn Med (Heidelb). 2024; 65(4):325-333.
PMID: 38456902
DOI: 10.1007/s00108-024-01679-2.
Clin Mol Hepatol. 2023; 29(3):542-592.
PMID: 37137334
PMC: 10366804.
DOI: 10.3350/cmh.2023.0087.
Saleem S, Inayat F, Khan A, Awan J, Goraya M, Hussain A
Prz Gastroenterol. 2023; 18(1):93-99.
PMID: 37007759
PMC: 10050982.
DOI: 10.5114/pg.2022.114540.
Standard immunosuppressive treatment reduces regulatory B cells in children with autoimmune liver disease.
Yuksel M, Nazmi F, Wardat D, Akgul S, Polat E, Akyildiz M
Front Immunol. 2023; 13:1053216.
PMID: 36685568
PMC: 9849683.
DOI: 10.3389/fimmu.2022.1053216.
Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial.
Snijders R, Stoelinga A, Gevers T, Pape S, Biewenga M, Verdonk R
Trials. 2022; 23(1):1012.
PMID: 36514163
PMC: 9745715.
DOI: 10.1186/s13063-022-06890-w.
Mycophenolate mofetil as second line treatment in autoimmune hepatitis - A retrospective single center analysis.
Kolev M, Diem S, Diem L, Rodrigues S, Berzigotti A, Stirnimann G
J Transl Autoimmun. 2022; 5:100172.
PMID: 36451933
PMC: 9702977.
DOI: 10.1016/j.jtauto.2022.100172.
Long-term results of mycophenolate mofetil . azathioprine use in individuals with autoimmune hepatitis.
Dalekos G, Arvaniti P, Gatselis N, Gabeta S, Samakidou A, Giannoulis G
JHEP Rep. 2022; 4(12):100601.
PMID: 36411768
PMC: 9674541.
DOI: 10.1016/j.jhepr.2022.100601.
Patient Priorities in Autoimmune Hepatitis: The Need for Better Treatments, More Education and Challenging Stigma.
Lloyd C, Leighton J, Wong L, Goulding A, Brownlee A, Gray P
Dig Dis Sci. 2022; 68(1):87-97.
PMID: 35579795
PMC: 9112273.
DOI: 10.1007/s10620-022-07525-5.
First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients.
Dalekos G, Arvaniti P, Gatselis N, Samakidou A, Gabeta S, Rigopoulou E
Front Immunol. 2022; 12:798602.
PMID: 35087524
PMC: 8787111.
DOI: 10.3389/fimmu.2021.798602.
Autoimmmune hepatitis.
Beretta-Piccoli B, Mieli-Vergani G, Vergani D
Cell Mol Immunol. 2021; 19(2):158-176.
PMID: 34580437
PMC: 8475398.
DOI: 10.1038/s41423-021-00768-8.
Development and validation of a prognostic score for long-term transplant-free survival in autoimmune hepatitis type 1.
Biewenga M, Verhelst X, Baven-Pronk M, Putter H, van den Berg A, van Nieuwkerk K
United European Gastroenterol J. 2021; 9(6):662-671.
PMID: 34165262
PMC: 8281048.
DOI: 10.1002/ueg2.12112.
The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis.
Wang G, Tanaka A, Zhao H, Jia J, Ma X, Harada K
Hepatol Int. 2021; 15(2):223-257.
PMID: 33942203
PMC: 8144150.
DOI: 10.1007/s12072-021-10170-1.
Early Predictors of Short-Term Prognosis in Acute and Acute Severe Autoimmune Hepatitis.
Biewenga M, Inderson A, Tushuizen M, Crobach A, van Hoek B
Liver Transpl. 2020; 26(12):1573-1581.
PMID: 32997870
PMC: 7756691.
DOI: 10.1002/lt.25906.
Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases.
Richardson N, Ng S, Wraith D
Front Immunol. 2020; 11:1586.
PMID: 32793226
PMC: 7385233.
DOI: 10.3389/fimmu.2020.01586.
Type 2 Autoimmune Hepatitis in a Male Patient with a Rare Complication of Vasculitis.
Shahid A, Punshi A, Khan B, Nazir M, Ullah H
Cureus. 2020; 12(3):e7354.
PMID: 32328366
PMC: 7170026.
DOI: 10.7759/cureus.7354.
Features and outcome of AIH patients without elevation of IgG.
Hartl J, Miquel R, Zachou K, Wong G, Asghar A, Pape S
JHEP Rep. 2020; 2(3):100094.
PMID: 32280942
PMC: 7139106.
DOI: 10.1016/j.jhepr.2020.100094.
Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination.
Czaja A
Clin Liver Dis (Hoboken). 2020; 15(Suppl 1):S72-S81.
PMID: 32140216
PMC: 7050953.
DOI: 10.1002/cld.917.
Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group.
Than N, Hodson J, Schmidt-Martin D, Taubert R, Wawman R, Botter M
JHEP Rep. 2020; 1(6):437-445.
PMID: 32039395
PMC: 7005655.
DOI: 10.1016/j.jhepr.2019.10.005.
